Literature DB >> 8273592

Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors.

K Molnar-Kimber1, L Yonno, R Heaslip, B Weichman.   

Abstract

The effect of selective PDE isozyme inhibitors including vinpocetine (PDE-I), CI-930 and milrinone (PDE-III), rolipram and nitraquazone (PDE-IV) and zaprinast (PDE-V) on monocyte viability and production of tumor necrosis factor (TNF alpha) and interleukin-1 beta (IL-1 beta) elicited from endotoxin-stimulated human monocytes was investigated. None of the inhibitors affected monocyte viability at 10 microM or lower concentrations. PDE-IV inhibitors and to a lesser extent, PDE-III inhibitors suppressed TNF alpha production. Only high concentrations of PDE-IV inhibitors modestly suppressed IL-1 beta. Zaprinast stimulated IL-1 beta and to a lesser extent TNF alpha production. These data show that TNF alpha and IL-1 beta production are differentially regulated, and that PDE III, PDE-IV and PDE-V isozymes are functional in endotoxin-stimulated monocytes. Clinical trials will be needed to ascertain if PDE-IV inhibitors are able to suppress TNF alpha levels in man.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8273592     DOI: 10.1007/bf01972726

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  8 in total

Review 1.  Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.

Authors:  C D Nicholson; R A Challiss; M Shahid
Journal:  Trends Pharmacol Sci       Date:  1991-01       Impact factor: 14.819

2.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

3.  Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP.

Authors:  C S Tannenbaum; T A Hamilton
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

4.  Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides.

Authors:  H Renz; J H Gong; A Schmidt; M Nain; D Gemsa
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

5.  Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase.

Authors:  G P Livi; P Kmetz; M M McHale; L B Cieslinski; G M Sathe; D P Taylor; R L Davis; T J Torphy; J M Balcarek
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

Review 6.  The biology of cachectin/TNF--a primary mediator of the host response.

Authors:  B Beutler; A Cerami
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

7.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.

Authors:  S Endres; H J Fülle; B Sinha; D Stoll; C A Dinarello; R Gerzer; P C Weber
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

8.  Cytokines in symptomatic asthma airways.

Authors:  D H Broide; M Lotz; A J Cuomo; D A Coburn; E C Federman; S I Wasserman
Journal:  J Allergy Clin Immunol       Date:  1992-05       Impact factor: 10.793

  8 in total
  10 in total

1.  The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Authors:  K H Banner; E Moriggi; B Da Ros; G Schioppacassi; C Semeraro; C P Page
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.

Authors:  D G Souza; G D Cassali; S Poole; M M Teixeira
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

4.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.

Authors:  S-L Catherine Jin; Marco Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

5.  Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease.

Authors:  Leila Gobejishvili; Shirish Barve; Swati Joshi-Barve; Craig McClain
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-07       Impact factor: 4.052

6.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

Review 7.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

8.  Intravenous milrinone for treatment of delayed cerebral ischaemia following subarachnoid haemorrhage: a pooled systematic review.

Authors:  Mendel Castle-Kirszbaum; Leon Lai; Julian Maingard; Hamed Asadi; R Andrew Danks; Tony Goldschlager; Ronil V Chandra
Journal:  Neurosurg Rev       Date:  2021-03-08       Impact factor: 3.042

9.  Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

Authors:  Fiona E McCann; Andrew C Palfreeman; Melanie Andrews; Dany P Perocheau; Julia J Inglis; Peter Schafer; Marc Feldmann; Richard O Williams; Fionula M Brennan
Journal:  Arthritis Res Ther       Date:  2010-06-02       Impact factor: 5.156

10.  Influence of pentoxifylline on gene expression of PAG1/ miR-1206/ SNHG14 in ischemic heart disease.

Authors:  Ahlam Abd El-Aziz; Mohamed Ali El-Desouky; Ayman Shafei; Mostafa Elnakib; Amr Mohamed Abdelmoniem
Journal:  Biochem Biophys Rep       Date:  2021-01-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.